Lack of acquired resistance in HER2-positive breast cancer cells after long-term HER2 siRNA nanoparticle treatment

Intrinsic and acquired resistance to current HER2 targeted therapies remains a challenge in clinics. We have developed a therapeutic HER2 siRNA delivered using mesoporous silica nanoparticles modified with polymers and conjugated with HER2 targeting antibodies. Our previous studies have shown that o...

Descripción completa

Detalles Bibliográficos
Autores principales: Gu, Shenda, Ngamcherdtrakul, Worapol, Reda, Moataz, Hu, Zhi, Gray, Joe W., Yantasee, Wassana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5991725/
https://www.ncbi.nlm.nih.gov/pubmed/29879129
http://dx.doi.org/10.1371/journal.pone.0198141

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5991725/
https://www.ncbi.nlm.nih.gov/pubmed/29879129
http://dx.doi.org/10.1371/journal.pone.0198141

Ejemplares similares